Evidence map›Paper›PMID 39797612›Full record

ArticleIntegrative cancer therapies

Long-Term Effects of Ozone Treatment in Patients with Persistent Numbness and Tingling Secondary to Chemotherapy-Induced Peripheral Neuropathy. A Retrospective Study.

Bernardino Clavo, Delvys Rodríguez-Abreu, Saray Galván-Ruiz, Mario Federico, Angeles Cánovas-Molina, Yolanda Ramallo-Fariña, Carla Antonilli, Gretel Benítez, Himar Fabelo, Carla García-Lourve and 4 more

3 registry-linked trialsAbstract read
In one paragraph

Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06799351 phase2 / phase3recruitingnot on this map

Evaluation of the Gut Microbiome Profiles in Patients with Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial with Ozone OzoParQT (NCT06706544).

TypeinterventionalSponsorBernardino Clavo, MD, PhDRan2025 to 2030Enrolled42ConditionsChemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia, Numbness, TinglingArmsOzone therapy, Oxygen (placebo)
NCT06816095 recruitingnot on this map

Gene and Molecular Pathway Characterization of the Response to Ozone Treatment in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Radio-chemotherapy

TypeobservationalSponsorBernardino Clavo, MD, PhDRan2025 to 2027Enrolled40ConditionsChronic Pelvic Pain Syndrome (CPPS), Radiation-Induced Disorder, Radiotherapy Side Effects, Side Effect of Chemotherapy
NCT07325851 not yet recruitingnot on this map

Prospective and Observational Study of Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029. Prospective Study EPOOzo-2.

Typeobservational_patient_registrySponsorBernardino Clavo, MD, PhDRan2026 to 2030Enrolled120ConditionsChemotherapy-Induced Peripheral Neuropathy, Radiation Toxicity, Chronic Pain, Delayed Wound HealingArmsOzone Therapy
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Bernardino ClavoHospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.ORCID 0000-0003-2522-1064
Delvys Rodríguez-AbreuComplejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Saray Galván-RuizHospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Mario FedericoHospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-6184-9070
Angeles Cánovas-MolinaHospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Yolanda Ramallo-FariñaFundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria/Tenerife, Spain.
Carla AntonilliHospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Gretel BenítezComplejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Himar FabeloFundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria/Tenerife, Spain.
Carla García-LourveHospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Damián González-BeltránHospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Ignacio J JorgeHospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Francisco Rodríguez-EsparragónHospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Gustavo M CallicoUniversity of Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNumbness and tingling secondary to chemotherapy-induced peripheral neuropathy (CIPN) are frequent side effects that limit chemotherapy treatment and quality of life. Successful treatments for CIPN are limited. This preliminary report shows the potential long-term effects of ozone treatment in the management of persistent numbness and tingling secondary to CIPN.

methodsOzone treatment was administered by rectal insufflation in 15 patients (female/male: 8/7, age: 66 years old) suffering from persistent numbness and tingling secondary to grade-2 or grade-3 CIPN. Planned ozone treatment consisted of 40 sessions over 4 months. The initial concentration of 10 μg/mL was progressively increased to 30 μg/mL. The initial gas volume of 180 mL/session was progressively increased to 300 mL/session if tolerated. Before and after ozone treatment, and at 3- and 6- months after the end of treatment, they were assessed (i) the grade of CIPN-toxicity, and (ii) the self-reported decrease in numbness and tingling.

resultsAfter ozone treatment, 47% of patients experienced a decrease in the grade of CIPN-toxicity (

conclusionsIn this retrospective report, patients with persistent numbness and tingling secondary to CIPN showed clinically relevant and long-term improvements after ozone treatment. The magnitude and duration of the observed effects merit further research and support our ongoing clinical trials.

Indexed as

Antineoplastic AgentsHypesthesiaOzonePeripheral Nervous System DiseasesAgedFemaleHumansMaleMiddle AgedNeoplasmsQuality of LifeRetrospective StudiesTreatment OutcomeAntineoplastic AgentsOzonecancer survivorschemotherapy-induced peripheral neuropathygrade of toxicityNrf2numbness and tinglingoxidative stress modulationozone treatmentparesthesiasside effects

Identifiers

PMID39797612
PMCPMC11724412

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.